Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On August 10, 2026, Erasca, Inc. (Nasdaq: ERAS), a company specializing in precision oncology, revealed the appointment of Charles S. Fuchs, M.D., M.P.H., as the president of research and development. Focusing on developing therapies for patients with RAS/MAPK pathway-driven cancers, Erasca's Board of Directors sanctioned the issuance of inducement awards to Dr. Fuchs.